Health and Fitness Health and Fitness
Mon, November 1, 2010
[ Mon, Nov 01st 2010 ] - Market Wire
I composti sperimentali per l'epatite C di Gilead .. azione con terapie standard di cura ottengono una
[ Mon, Nov 01st 2010 ] - Market Wire
Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention
[ Mon, Nov 01st 2010 ] - Market Wire
Health Management Associates, Inc. to Present at the Oppenheimer 21st Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Porex Corporation Divests Surgical Division to Stryker Corporation
[ Mon, Nov 01st 2010 ] - Market Wire
Medisafe 1 Technologies Appoints Tali Skoczylas as Chair of Medical Advisory Board
Sat, October 30, 2010
[ Sat, Oct 30th 2010 ] - Market Wire
A Celgene anuncia resultados financeiros e operacionais recordes no terceiro trimestre de 2010
[ Sat, Oct 30th 2010 ] - Market Wire
Viread® for Hepatitis B Maintains Antiviral Supp .. ent of Resistance Through Four Years of Treatment
[ Sat, Oct 30th 2010 ] - Market Wire
New Data From Phase 3 Studies Showed Superior SVR .. with Telaprevir-Based Combination Therapy in Peop
[ Sat, Oct 30th 2010 ] - Market Wire
Salix Pharmaceuticals Previews Data Slated for Pr .. ting of the American Association for the Study of
[ Sat, Oct 30th 2010 ] - Market Wire
Gileada?s Investigational Hepatitis C Compounds G .. tion with Standard of Care Therapies Achieve Subs
Fri, October 29, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Announces a Stron .. eement with Majority of Senior Subordinated Noteh
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
[ Fri, Oct 29th 2010 ] - Market Wire
Forest Announces FDA Approval of Teflaroa" (cefta .. ment of Community-Acquired Bacterial Pneumonia an
[ Fri, Oct 29th 2010 ] - Market Wire
FDA Classifies Previous Field Action of Medtronic Surgical Device as Class I Recall
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Present at Two Upcoming Investor Conferences
[ Fri, Oct 29th 2010 ] - Market Wire
ArthroCare Announces Third Quarter 2010 Financial Results Press Release and Conference Call Dates
[ Fri, Oct 29th 2010 ] - Market Wire
Wright Medical Group, Inc. to Participate in the 2010 Annual Credit Suisse Healthcare Conference
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 9, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Fitch Affirms Boston Scientific's IDR at 'BB+'; Outlook to Positive
[ Fri, Oct 29th 2010 ] - Market Wire
Ligand to Report Third Quarter Results on November 9
[ Fri, Oct 29th 2010 ] - Market Wire
Teva Invites Public to Listen to Its Respiratory Opportunity Meeting Webcast
[ Fri, Oct 29th 2010 ] - Market Wire
Amedisys to Present at Three Upcoming Conferences
[ Fri, Oct 29th 2010 ] - Market Wire
Kendall Law Group Investigates BMP Sunstone Corporation Acquisition for Shareholders
[ Fri, Oct 29th 2010 ] - Market Wire
St. Jude Medical???2010??????????????
[ Fri, Oct 29th 2010 ] - Market Wire
CORRECTING and REPLACING Abstracts Highlighting D .. nist Programs Accepted for Presentation at 2010 E
[ Fri, Oct 29th 2010 ] - Market Wire
Celgene meldet rekordverdchtiges Betriebs- und Finanzergebnis fr das dritte Quartal 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Zynex Ranked 8th in Growth Among Medical Equipment Companies.
[ Fri, Oct 29th 2010 ] - Market Wire
China Kanghui Holdings to Report Third Quarter 2010 Financial Results
[ Fri, Oct 29th 2010 ] - Market Wire
AVEO Pharmaceuticals Announces $61 Million Private Placement
[ Fri, Oct 29th 2010 ] - Market Wire
Seattle Genetics to Present at Oppenheimer Healthcare Conference

Seattle Genetics to Present at Oppenheimer Healthcare Conference


Published on 2010-10-29 06:11:32 - Market Wire
  Print publication without navigation


BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that its management will present a company overview at the Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010, at 1:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Geneticsa™ website, [ www.seattlegenetics.com ], under the aInvestors and Newsa section.

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company recently reported positive top-line data from both a pivotal Hodgkin lymphoma trial and phase II anaplastic large cell lymphoma trial with its lead product candidate, brentuximab vedotin, and plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].

Contributing Sources